Cell Culture Technology– category –
-
Sartorius Unveils Next-Gen Lab Balance ‘Cubis III,’ Enhancing Data Integrity with 21 CFR Part 11 Compliance
Chromatography Online USA Overview Sartorius has launched 'Cubis III,' its latest generation of laboratory balances, offering direct embedded connectivity to digital environments, eliminating the need for middleware and significantly red... -
Benchling Launches ISA-88 Compliant Cloud-Native Bioprocess Platform to Enable High-Throughput Process Development
Benchling USA Overview Benchling has introduced "Benchling Bioprocess," a cloud-native platform featuring an ISA-88 compliant data model to enable high-throughput, structured process development. This integrated environment streamlines p... -
Cellbase Guide: Perfusion Culture Unlocks 10^9 Cells/mL, Revolutionizing Bioreactor Productivity
Cellbase フィンランド Overview Cellbase's new guide on bioreactor scale-up highlights perfusion culture as a critical technology for achieving unprecedented cell densities, often reaching 10^7–10^8 cells/mL and potentially up to 10^9 cel... -
Bispecific Antibody CDMO Market to Surge to $603.13 Billion by 2035, Driven by Diverse Asymmetric Formats
PharmaSource UK Overview This article outlines a market research report from PharmaSource on the bispecific antibody CDMO market, projected to skyrocket from $25.94 billion in 2026 to approximately $603.13 billion by 2035. A key market t... -
EU NK Cell Market Projected for Twofold Growth by 2035, Driven by Increasing Allogeneic NK Cell Therapy Approvals
IndexBox USA Overview This article outlines a report from IndexBox on the European Union's NK cell market, which is expected to double in size between 2026 and 2035. This growth is primarily driven by the approval and commercial launch o... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
FUJIFILM Completes £400M UK Teesside CDMO Expansion, Accelerating Bioprocess Innovation and Cell Product Diversification
Fujifilm Japan Overview FUJIFILM announced significant life sciences advancements at BIO 2026, notably completing a £400 million investment in its UK Teesside manufacturing facility, making it the largest single-use CDMO site in the coun... -
Ernexa Therapeutics Accelerates iPSC-Derived MSC Manufacturing with Japan JEAP Selection, Highlighting Japan’s CDMO Ecosystem as Key
Clinical Leader USA Overview Ernexa Therapeutics has been selected for Japan's Entry Acceleration Program (JEAP), gaining a critical opportunity to advance its induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) pla... -
U.S. Stem Cell Manufacturing Market Forecast to Reach $4.04 Billion, Driven by Innovative Technologies and Automation from Thermo Fisher, Lonza, and Sartorius
openPR.com USA Overview This article summarizes a report on the U.S. stem cell manufacturing market, projected to reach $4.04 billion, driven by innovative technologies and strategic initiatives from key players. Thermo Fisher Scientific... -
WuXi Biologics Suzhou BioSafety Testing Center Secures Fourth EMA GMP Certification, Enabling 19 Commercial Products for European Market
WuXi Biologics China Overview WuXi Biologics' Suzhou BioSafety Testing Center has successfully renewed its European Medicines Agency (EMA) GMP certification for the fourth time. This accreditation enables the center to support quality te...
